Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer Maria Cristina RangelDaniel BertoletteDavid S. Salomon Review Open access 11 March 2016 Pages: 211 - 226
A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis Tomohiro F. NishijimaMaya SuzukiHyman B. Muss Review 17 March 2016 Pages: 227 - 236
Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer Hirofumi MatsumotoAye Aye ThikeJabed Iqbal Preclinical study 09 March 2016 Pages: 237 - 247
A novel gene expression signature for bone metastasis in breast carcinomas C. Dilara Savci-HeijinkHans HalfwerkMarc J. van de Vijver Preclinical study Open access 10 March 2016 Pages: 249 - 259
Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype Kumiko KidaTakashi IshikawaItaru Endo Preclinical study 14 March 2016 Pages: 261 - 269
Is ultrasound-guided fine-needle aspiration cytology of adequate value in detecting breast cancer patients with three or more positive axillary lymph nodes? G. M. KramerM. W. H. LeendersW. H. Schreurs Preclinical study 19 March 2016 Pages: 271 - 278
Equivalence of MammaPrint array types in clinical trials and diagnostics Inès BeumerAnke WitteveenAnnuska Glas Preclinical study Open access 22 March 2016 Pages: 279 - 287
Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany Lisa VetterMonika KellerSarah Schott Clinical Trial 09 March 2016 Pages: 289 - 299
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer Giuseppe CuriglianoGilles RomieuFrédéric F. Lehmann Clinical trial 14 March 2016 Pages: 301 - 310
Should the hyperechogenic halo around malignant breast lesions be included in the measurement of tumor size? Judith JoekelHolm EggemannAtanas Ignatov Clinical trial 17 March 2016 Pages: 311 - 317
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors Steven A. LimentaniMario CamponeFrédéric F. Lehmann Clinical trial 18 March 2016 Pages: 319 - 330
Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients Emilie HéninChristophe MeilleGilles Freyer Clinical trial 22 March 2016 Pages: 331 - 341
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27 Judith-Anne W. ChapmanLois E. ShepherdPaul E. Goss Clinical trial 23 March 2016 Pages: 343 - 349
Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer Devon K. CheckKatherine E. Reeder-HayesStacie B. Dusetzina Epidemiology 11 March 2016 Pages: 351 - 359
The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis Charla C. EngelsMandy KiderlenGerrit Jan Liefers Epidemiology Open access 11 March 2016 Pages: 361 - 370
The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients T. HuzarskiT. ByrskiThe Polish Breast Cancer Consortium Epidemiology 17 March 2016 Pages: 371 - 378
Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen Marilyn L. KwanJiaxiao M. ShiReina Haque Epidemiology 22 March 2016 Pages: 379 - 389
Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period S. C. J. BosmaF. van der LeijP. H. M. Elkhuizen Epidemiology 23 March 2016 Pages: 391 - 400
Erratum to: Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue Myriam VilascoLaudine CommunalBRACAPS Erratum 08 March 2016 Pages: 401 - 402
Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients Jun TangRong DengXiao-Feng Zhu Erratum 09 March 2016 Pages: 403 - 404
Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy Seth A. WanderDekuang ZhaoJoyce M. Slingerland Erratum 18 March 2016 Pages: 405 - 406
Erratum to: RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial–mesenchymal transition Chonggao YinHongli LiWeiyi Chen Erratum 21 March 2016 Pages: 407 - 408
Erratum to: Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter V. BartellaP. RizzaS. Andò Erratum 23 March 2016 Pages: 409 - 409